00000000cam 2200000zi 4500
0019.967064
003CaOODSP
00520261102160737
006m     o  d f      
007cr cn|||||||||
008261021e202610##onc     ob   f000 0 eng d
020 |a9781100010700
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH169-14/2026E-PDF
24500|aGuidance for clinical trials with decentralized elements.
264 1|aOttawa ON : |bHealth Canada = Santé Canada, |cOctober 2026.
264 4|c©2026
300 |a1 online resource (iii, 52 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aTitle from cover.
500 |aIssued also in French under title: Lignes directrices pour les essais cliniques avec des éléments décentralisés.
500 |a"Health products."
504 |aIncludes bibliographical references (pages 50-51).
520 |a"This guidance outlines regulatory considerations for conducting clinical trials with decentralized elements in Canada. These considerations are supported by Part C, Division 5 of the Food and Drug Regulations (FDR) and the International Council for Harmonisation’s Guideline for Good Clinical Practice (ICH E6)"--Overview, Purpose, page 1.
650 0|aDrugs|xTesting|xGovernment policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
7101 |aCanada.|bPharmaceutical Drugs Directorate, |eissuing body.
7101 |aCanada. |bBiologic and Radiopharmaceutical Drugs Directorate, |eissuing body.
77508|tLignes directrices pour les essais cliniques avec des éléments décentralisés.|w(CaOODSP)9.967065
85640|qPDF|s835 KB|uhttps://publications.gc.ca/collections/collection_2026/sc-hc/H169-14-2026-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/clinical-trials-decentralized-elements.html